You have read all your free articles, to continue reading subscribe to read the rest of this content.
Sprint Bioscience and the US drug development company Petra Pharma Corporation have entered into a collaboration and license agreement for the research, development, and commercialization of Sprint Bioscience’s PIP4K2a program targeting tumor metabolism. Under the agreement, Sprint Bioscience lAlready a subscriber Login You have read all your free articles, to…
The company has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royaltiAlready a subscriber Login You have…
The company has signed an agreement with pharmaceutical wholesaler Pharmaxim to distribute ColdZyme at Swedish airports. Air-passengers are an important target group for Enzymatica’s cold treatment spray, claims the company, refering to a US study which has shown that one in five passengers caAlready a subscriber Login You have read all…
Modus Therapeutics secures access to bridge financing from longstanding investor Karolinska Development. Access to this funding ensures that momentum of clinical development of Modus’ lead asset, sevuparin, will be enhanced while the company continues to explore licensing and partnership opportAlready a subscriber Login You have read all your free articles,…
